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Abstract: Joint replacement has proven to be an extremely successful and cost-effective 
means of relieving arthritic pain and improving quality of life for recipients. Wear  
debris-induced osteolysis is, however, a major limitation and causes orthopaedic implant 
aseptic loosening, and various cell types including macrophages, monocytes, osteoblasts, 
and osteoclasts, are involved. During the last few years, there has been increasing concern 
about metal-on-metal (MoM) hip replacements regarding adverse reactions to metal debris 
associated with the MoM articulation. Even though MoM-bearing technology was initially 
aimed to extend the durability of hip replacements and to reduce the requirement for 
revision, they have been reported to release at least three times more cobalt and chromium 
ions than metal-on-polyethylene (MoP) hip replacements. As a result, the toxicity of metal 
particles and ions produced by bearing surfaces, both locally in the periprosthetic space 
and systemically, became a concern. Several investigations have been carried out to 
understand the mechanisms responsible for the adverse response to metal wear debris. This  
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review aims at summarising in vitro analyses of the toxicity, immunological, and gene 
expression effects of cobalt ions and wear debris derived from MoM hip implants. 
Keywords: wear debris; cobalt; metal-on-metal; hip implants 
 
1. Introduction 
Joint replacement has proven to be an extremely successful and cost-effective means of relieving 
arthritic pain and improving quality of life for recipients [1]. A primary replacement is an initial 
replacement procedure undertaken on a joint and involves replacing either part (partial) or all (total) of the 
articular surface. Revision hip replacements are repeat-operations of previous hip replacements where one 
or more of the prosthetic components are replaced, removed, or one or more components are added [2]. 
The total number of joint replacement procedures recorded by the National Joint Registry of England, 
Wales, and Northern Ireland (NJR) exceeded 1.6 million records between 1 April 2003 and 31 March 
2013, with 2012/13 having the highest ever annual number of submissions at 205,686. The total number of 
primary hip procedures was 620,400. Of these, 76,274 were entered into the NJR during 2013, as reported 
in the NJR 11th Annual Report [3]. Similarly, there have been 410,767 hip replacements reported to the 
Australian Registry up to 31 December 2013. Of these, 40,180 were entered during 2013 [2]. 
Total joint replacement surgery has traditionally been reserved for elderly patients with advanced 
arthrosis who postoperatively would be less active. However, this scenario has now substantially changed, 
and many patients now receive total hip arthroplasty at a younger age. For example, Furnes et al. [4] 
compared implant survival of metal-on-metal (MoM) with that of metal-on-highly-cross-linked-polyethylene 
in patients between 45 and 64 years old. Kanda et al. [5] reported the case of a 42-year-old patient 
presenting with femoral head migration after an arthroplasty performed 22 years earlier. Moreover, it has 
been estimated that 10,000 to 30,000 patients less than 25 years of age have undergone joint replacement 
procedures in the last five years, and it is likely that many of those are paediatric patients [6]. It can also be 
anticipated that the rate of joint replacement in paediatric patients will increase, particularly given the 
popularity of this surgery and the incidence of diagnoses that may result in joint replacement surgery. 
Currently, over 294,000 individuals younger than 21 years of age are estimated to have juvenile  
arthritis [7]. The clinical outcome is generally excellent, but many young patients still need implant 
replacement within 1015 years [8], and some may experience complications, including implant failure. 
Out of the 620,400 procedures recorded by the NJR, 14,903 had an associated first revision. The most 
commonly cited indications were aseptic loosening (cited in 3659 procedures), pain (3489), dislocation/ 
subluxation (2545), and infection (2072) [3]. In accordance with this, the Australian registry reported the 
most common reasons for revision of primary total conventional hip replacement were loosening/lysis 
(2550 procedures), followed by prosthesis dislocation (2251), fracture (1576), and infection (1534) [2]. 
Wear debris-induced osteolysis is a major cause of orthopaedic implant aseptic loosening, and 
various cell types including macrophages, monocytes, osteoblasts, and osteoclasts are involved [9]. 
During the last few years, there has been increasing concern about MoM hip replacements regarding 
adverse reactions to metal debris associated with the MoM articulation [10]. As a consequence, on  
22 July 2008, there was a voluntary recall of the Zimmer Durom® Acetabular Component (Durom Cup) 
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because the instructions for use/surgical technique were inadequate, which led to a higher than expected 
revision rate. Following this, on 24 August 2010, there was a voluntary recall of the DePuy ASR total 
hip system because of new, unpublished data from the UK joint registry indicating the revision rates within 
five years were approximately 13%. Two years later, on 1 June 2012, Smith & Nephew Orthopaedics 
initiated a market withdrawal for metal liners of the R3 acetabular system due to a higher than expected 
number of revision surgeries associated with the use of the device in total hip replacements outside the  
US [11]. Since a patient with an adverse reaction to metal debris can be asymptomatic [12], may have low 
metal ion levels [13], and may have normal cross-sectional imaging [14], diagnosing an adverse reaction is 
challenging. Even though MoM-bearing technology was initially aimed to extend the durability of hip 
replacements and to reduce the requirement for revision, they have been reported to release at least three 
times more cobalt and chromium ions than metal-on-polyethylene (MoP) hip replacements [15,16]. As a 
result, the toxicity of metal particles and ions produced by bearing surfaces, both locally in the 
periprosthetic space and systemically, became a concern [17]. Several investigations have been carried out 
to understand the mechanisms responsible for the adverse response to metal wear debris. This review aims 
at summarising in vitro analyses of the toxicity, immunological, and gene expression effects of cobalt ions 
and wear debris derived from MoM hip implants. 
2. Wear Particle Generation and Metal Ion Release 
The degradation products of any orthopaedic implant include two basic types of debris: particles and 
soluble (or ionic) debris [18]. MoM joints are exposed to a complex in vivo environment with 
mechanical and electrochemical degradation mechanisms that influence the longevity of the device [19]. 
The wear of MoM joints is of particular concern because particulate debris and release of Co/Cr ions 
can lead to adverse tissue reactions including necrosis, hypersensitivity, and pseudotumors [20,21]. 
Wear characteristics of MoM total hip replacements have two distinctive stages. Initially, the femoral 
and acetabular components show a relatively rapid but decreasing wear rate over the first 12 × 106 
cycles in a hip joint simulator, or for one or two years in vivo, generally referred to as the bedding-in 
or running-in stage. Once this process has been completed, the rate of wear becomes reasonably 
steady and hence is referred to as steady-state [22,23]. Most wear debris particles are created in the 
running-in phase [23]. Wear debris is released from the articular surfaces after joint arthroplasty as a 
result of friction between articulating implant components or between cement and implant [24]. There 
are three types of mechanical wear mechanisms: fatigue, abrasive, and adhesive [9]. The first is caused 
by cyclic stresses inducing micro-fractures to occur within materials due to fatigue; once these  
micro-fractures reach the surface, wear particles are generated through delamination [25]. Abrasive 
wear can be split into two sub-categories; two-body and three-body. Two-body abrasive wear involves 
the roughness of a hard surface in contact with a softer material; particulates are released from the 
softer material due to ploughing. Three-body abrasive wear involves three materials instead; for 
example, they can include bone cement or fragments of bone between two articulating surfaces. 
Finally, adhesive wear involves intermolecular bonds of the weaker material bonding to the stronger 
material, resulting in shearing [9]. 
Metal corrosion is the degradation process affecting the surface of metallic materials due to their 
reaction with the surrounding environment. Most metallic materials are susceptible to corrosion attack 
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if a tenacious surface oxide layer does not exist. Where the surface layer is permeable to oxygen and 
moisture, the corrosion process will continue and lead to eventual failure. Among the variety of 
corrosion mechanisms, metal corrosion is driven mainly by electrochemical potential. During exposure 
to aqueous environments, atoms of the metal surface experience an anodic process; electrons are 
released from the atoms forming metallic ions (oxidation). The localized electrical potential accelerates 
the oxidation process until the electrochemical potential is balanced [26]. Fretting corrosion is a type 
of mechanically assisted chemical degradation. Fretting corrosion damage is determined by a 
combination of metal atom dissolution through the fractured passive layer and metal oxide reformation. 
The oxide film is fractured by the contact and friction of rough articulating surfaces and exposure of 
the pure metal surface to a corrosive medium [27,28]. The physiological environment is considered 
corrosive. This makes the corrosion of metallic materials a slow and continuous process, which leads 
to the release of metal ions [29,30]. Corrosion damage is a very important issue for metallic implants 
that can affect their biocompatibility and mechanical integrity [31]. Chloride ions, amino acids, and 
proteins in the body can accelerate corrosion. Metallic biomaterials in aqueous solutions comprise 
active and passive surfaces that are simultaneously in contact with electrolytes. In this environment, the 
surface oxide film repeats a process of partial dissolution and re-precipitation. Metal ions are gradually 
released when dissolution is faster than re-precipitation [32]. Under physiological conditions, corrosion 
occurs as an electrochemical process in which electron exchange occurs at the metal surface [33]. The 
rate of this phenomenon is determined, in part, by the surface area. Since wear debris released from 
metal components is, for the most part, in the nanometre size range, it has a high surface area that 
increases the rate of corrosion [28]. When CoCr alloy is in contact with body fluids, cobalt is 
completely dissolved, and the surface oxide changes into chromium oxide containing a small amount 
of molybdenum oxide [34]. Elevated levels of Co and Cr ions occur in the peripheral blood and in the 
hip synovial fluid after CoCr alloy MoM hip replacement, and there is concern about the toxicity and 
biological effects of such ions both locally and systemically [35,36] (Table 1). 
It has been reported that 20%30% material loss can be attributed to corrosion-related damage, and 
that not only includes the pure corrosion process but also the wear induced/enhanced corrosion process 
that is defined as tribocorrosion [23]. Mechanically assisted corrosion, also referred to as tribocorrosion, 
is an irreversible process that occurs on the surface causing a deterioration of the material due to the 
combined wear and corrosion actions that simultaneously take place [31]. Tribocorrosion, present at 
bearing surfaces and within modular taper connections between components of the arthroplasty device, 
has been proposed to be the primary process by which ions and particles are generated [37]. The 
released ions can activate the immune system by forming complexes with native proteins [38]. 
Chromium and cobalt have similar protein binding affinity, and bind to proteins in proportion to the 
concentration ratio [39]. Once a metal is bound to a protein, it can be systemically transported and 
either stored or excreted [28]. Additionally, the presence of wear debris in the peri-implant area leads 
to macrophage phagocytosis of particulate debris and activation to stimulation of the release of a 
variety of mediators, such as free radicals and nitric oxide, and a myriad of proinflammatory cytokines 
and chemokines [40]. It has been reported that local acidification may develop during acute and 
chronic inflammation [41] and high hydrogen ion concentrations down to pH 5.4 have been found in 
inflamed tissue [42]. In turn, such an acidic environment, created by actively metabolizing immune 
cells, may enhance the corrosion process, increasing the metal ions being released. To illustrate this, 
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Posada et al. [43] showed that significantly higher concentrations of Co and Cr were released when 
CoCr metal wear debris were incubated at low pH (Figure 1). Their findings suggest that the osteolysis 
process generated by wear debris may be exacerbated by the lowering of pH at an inflammation site. 
This is in line with reports of synovial fluid acidosis correlating with radiological joint destruction in 
rheumatoid-arthritis knee joints [44,45]. 
 
Figure 1. Metal ions released in vitro from CoCr alloy into RPMI-1640 medium at pH 7.4 
and 4.0. Results are expressed as mean values (±standard error of the mean (SEM), n = 3). 
FCS = foetal calf serum. * Significantly different from control values (p < 0.05) by one-way 
Analysis Of Variance (ANOVA) followed by Dunnetts multiple comparison test. 
Significant difference between pH 7.4 and pH 4.0. 
2.1. Chromium 
After entering the body from an exogenous source, Cr3+ binds to plasma proteins such as transferrin, 
an iron-transporting protein. Regardless of the source, Cr3+ is widely distributed in the body and 
accounts for most of the chromium in plasma or tissues. The Cr3+ is taken up as a protein complex into 
bone marrow, lungs, lymph nodes, spleen, kidney, and liver, with the highest uptake being in the  
lungs [46]. It has been shown that cell membranes are relatively impermeable to Cr3+. When varying 
amounts of radioactive Cr3+ were added to whole blood in vitro, almost all of the radioactivity (94%99%) 
remained in the plasma with an insignificant amount retained in the red blood cells (RBC). Similar 
results were obtained in vivo [47]. Similarly, low permeability of Cr3+ was found in Chinese hamster 
lung V79 cells exposed to Cr3+ complexes [48]. Additionally, it has been shown that the cellular uptake 
of Cr6+ is several-fold greater than that of Cr3+ ion, because trivalent chromium is predominantly 
octahedral and diffuses slowly [49]. In contrast to Cr3+, Cr6+ is rapidly taken up by RBCs and reduced 
to Cr3+ inside the cell. Cr6+ enters the cell through non-specific anionic channels, such as the phosphate 
and sulphate anion exchange pathway [50,51]. Once within the cell, Cr6+ is reduced metabolically by 
the redox system to short-lived intermediates Cr5+, Cr4+, and ultimately to the most stable species  
Cr3+ [5254]. Cr3+ interacts and forms complexes with DNA, protein, and lipids resulting in increased 
chromium intracellular levels [5153]. 
pH7.4RPMI ?FCS
+Co ?Crwear
debris
RPMI+10%FCS
(control)
RPMI+10%FCS+
Co ?Crweardebris
pH4RPMI+10%
FCS+Co ?Crwear
debris
Cr 15.91 0.19 18.18 372.10
Co 122.56 0.09 1259.41 3182.85
Mo 127.82 6.32 124.6 222.26
0
500
1000
1500
2000
2500
3000
3500
M
e
a
n
Co
n
ce
n
tr
a
ti
o
n
[µ
g
/L
]±
S
E
M
Lubricants 2015, 3 544 
 
Table 1. Metal ion levels measured in whole blood and synovial fluid from patients with metal-on-metal (MoM) hip replacements. 
Author Implant Body fluid Follow up 
Mean Concentration (µg/L) 
 Co Cr 
Daniel, et al. [55] MoM resurfacing Whole blood Up to 4 years 
Pre-op 0.2 0.3 
1 year 1.3 2.4 
4 years 1.2 1.1 
Ziaee, et al. [56] MoM resurfacing Whole blood Mean of 53 months 
Control 0.3 0.2 
Patients 1.4 1.9 
Antoniou, et al. [57] MoM (THA and resurfacing), MoP (THA) Whole blood 1 year 
Control 1.8 0.1 
MoM THA 2.6 0.6 
MoM resurfacing 2.4 0.5 
MoP THA 1.7 0.1 
non-steep (component abduction <55°) 2.4 3.6 
Wretenberg [58] MoM THA (Case report) Whole blood 37 years - 22.9 19.4 
Hart, et al. [59] Painful MoM resurfacings Whole blood median of 27 months
Unilateral 4.5 * 3.0 * 
Bilateral 10.6 * 7.9 * 
Hart, et al. [60] Failed MoM resurfacing Whole blood Mean 51 months - 112.6 61.7 
Langton, et al. [61] MoM resurfacing (ASR, BHR) Whole blood 
minimum of  
12 months 
ASR 2.7 * 4.2 * 
BHR 1.8 * 4.2 * 
Adverse reactions 69.0 29.3 
Davda, et al. [62] Symptomatic MoM, THA and resurfacing Synovial fluid Mean of 36 months 
Unexplained pain 1127.0 * 1337.0 * 
Defined cause of failure 1014.0 * 1512.0 * 
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Table 1. Cont. 
Author Implant Body fluid Follow up 
Mean Concentration (µg/L) 
 Co Cr 
Hart, et al. [63] MoM, THA and resurfacing Whole blood 3942 months 
Failed 6.9 * 5.0 * 
Well-functioning 1.7 * 2.3 * 
Non-pseudotumor 1.9 * 2.1 * 
Pseudotumor 9.2 * 12.0 * 
Malviya, et al. [64] MoM, MoP, THA Whole blood 2 years 
MoM 5.2 2.8 
MoP 1.6 0.8 
Fritzsche, et al. [65]
bilateral MoM resurfacing followed  
by unilateral MoM THA (Case report) 
Whole blood, aspirate 
of pseudotumor 
3 months after  
revision surgery 
Blood 138.0 39.0 
Aspirate of pseudotumor 258.0 1011.0 
Well-functioning 2.3 1.6 
Matthies, et al. [66] MoM, THA and resurfacing Whole blood Median of 39 months
No pseudotumor 2.9 3.2 
Pseudotumor 11.0 6.7 
Lass, et al. [67] MoM, THA Synovial fluid minimum of 18 years - 113.4 * 54.0 * 
* Ion concentrations expressed as median values. Pre-op = previous to operation, THA = total hip arthroplasty, MoM = metal-on-metal, MoP = metal-on-polyethylene, 
BHR = Birmingham Hip Resurfacing, ASR = Acetabular System Resurfacing, DePuy. 
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Excretion of Cr occurs primarily via urine, with no major retention in organs. Approximately 10% 
of an absorbed dose is eliminated by biliary excretion, with smaller amounts excreted in hair, nails, 
milk, and sweat. Clearance from plasma is generally rapid (within hours), whereas elimination from 
tissues is slower (with a half-life of several days) [68]. 
The toxicity, mutagenicity, and carcinogenicity of chromium compounds are well-established 
phenomena [46,50,69,70]. Long-term occupational inhalational exposure to Cr levels 1001000 times 
higher than those found in the natural environment have been associated with squamous cell carcinoma 
and adenocarcinoma in exposed workers [71]. Epidemiological studies carried out in the UK, Europe, 
Japan, and the United States have consistently shown that workers in occupations where particulate 
chromates are generated or used have an elevated risk of respiratory disease, fibrosis, perforation of the 
nasal septum, development of nasal polyps, and lung cancer [72]. Additionally, during the intracellular 
reduction of Cr6+ to the stable Cr3+, reactive intermediates (for example, reactive oxygen species 
(ROS), pentavalent and tetravalent chromium species) are generated, which causes a wide variety of 
DNA lesions including Cr-DNA adducts, DNA-protein crosslinks, DNA-DNA crosslinks, and 
oxidative damage [68,73]. 
Cr toxicity is associated with its oxidation state. However, it is still controversial whether Cr is 
released as Cr6+ in patients with MoM devices, with some reports supporting this idea and others 
disproving it [60,70,74]. In the authors experience, analysis of the speciation of Cr is fraught with 
difficulty due to the instability of Cr6+, which tends to oxidise to Cr3+ very rapidly. There is a general 
consensus, however, that Cr(III) is elevated in the biological fluids of all patients with MoM-type 
implants [63,75]. 
2.2. Cobalt 
For the general population, diet is the main source of exposure to Co and it is readily absorbed from 
the small intestine [68,76]. Most of the consumed Co is excreted in the urine and the little that is 
retained is mainly in the liver and kidneys [68]. Under physiological conditions, this element is mostly 
accumulated in the liver, kidneys, heart, and spleen, while minimum concentrations are found in the 
blood serum and tissues of the brain and pancreas [77]. Molecular details of the mode of Co uptake 
into cells are not well known [76,78]. However, it is likely that it is transported into the cells by  
broad-specificity divalent metal transporters [78]. It has been shown that P2X7, a transmembrane 
ionotropic receptor, is involved in the uptake of divalent cations and Co [79]. In the same way, a 
protein named divalent metal transporter 1 (DMT1) has been shown to have a broad substrate 
specificity favouring divalent metals including Co2+ [8082]. Additionally, the cellular uptake of Co 
may be mediated both by active transport ion pumps (i.e., Ca2+/Mg2+ ATPase and Na+/K+ ATPase) and 
endocytosis [84]. 
The only biological known function of Co is as an integral part of vitamin B12, which is 
incorporated into enzymes that participate in reactions essential to DNA synthesis, fatty acid synthesis, 
and energy production [76,78]. Even though Co has a role in biological systems, overexposure results 
in toxicity [78], which involves development of hypoxia, increases in the level of ROS, suppression of 
Adenosine triphosphate (ATP) synthesis, and initiation of apoptotic and necrotic cell death [77]. Co 
ions can directly induce DNA damage, interfere with DNA repair, and cause DNA-protein crosslinking 
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and sister chromatid exchange [68]. The exact mechanism for Co carcinogenicity remains to be 
elucidated, but it has been established that free radical generation contributes to its toxicity and 
carcinogenicity [83]. 
3. Biological Effects 
3.1. Toxicity 
Particulate wear debris generated by MoM has an average particle size range of 30 to 100 nm [84]. 
The reduced size of the particles allows their entry into tissues and organs and diffusion throughout the 
body, and interaction with different types of cells [85]. Concern about the toxicity of such particles has 
led to a number of studies assessing the effects of CoCr metal wear debris in vitro on a variety of  
cells [8688]. It has been established that both Co ions and Co nanoparticles are cytotoxic and induce 
apoptosis and, at high concentrations, they induce necrosis with an inflammatory response [89]. 
Papageorgiou et al. [86] compared the cytotoxic and genotoxic effects of nanoparticles and micron-sized 
particles of CoCr alloy using human fibroblasts. Their results showed that exposure to both nano- and 
micron-sized particles of CoCr alloy, at the same particle mass per cell, causes different types and 
amounts of cellular damage. Posada et al. [88] investigated the effects of the combined exposure to 
CoCr nanoparticles and cobalt ions released from a resurfacing implant on monocytes (U937 cells), 
and used much lower concentrations of nanoparticles than the previous study [85]. They showed that 
metal debris in combination with Co ions had a direct effect on cell viability. Interestingly, they 
showed that previous exposure to Co ions seems to sensitise U937 cells to the toxic effects of both Co 
ions themselves and to nanoparticles, pointing to the potential for interaction in vivo. Their results 
indicate that even low doses of CoCr nanoparticles can exert cytotoxic effects. Dalal et al. [87] 
compared the responses of human osteoblasts, fibroblasts, and macrophages exposed to different 
metal-based particles (i.e., cobalt-chromium (CoCr) alloy, titanium (Ti) alloy, zirconium (Zr) oxide, 
and Zr alloy). They found that CoCr-alloy particles were by far the most toxic and decreased viability 
and proliferation of human osteoblasts, fibroblasts, and macrophages. VanOs et al. [90] used 
commercially available 60 nm and 700 nm round chromium oxide (Cr2O3) particles to analyse the 
cytotoxic effects of chromium oxide particles on macrophage responses in vitro. With both particle 
sizes, cell mortality increased, resulting in a significant decrease in total cell numbers, as well as a 
significant increase in late apoptosis and necrosis. Tsaousi et al. [91] investigated the in vitro 
cytotoxicity and genotoxic effects of alumina ceramic (Al2O3) particles in comparison with CoCr alloy 
particles. They found no significant differences in cell viability between control and ceramic-treated 
cells, at all doses and time-points studied. However, and in agreement with the studies mentioned 
above, cells exposed to CoCr alloy particles showed both dose- and time-dependent cytotoxicity 
including damage to, and loss of, chromosomes. 
The apoptotic effects of Co ions have mainly been reported at concentrations starting from  
100 ȝM, where Co induced cell death and apoptosis in a dose- and time-dependent manner [9294]. 
Catelas et al. [95] demonstrated that macrophage mortality induced by metal ions depends on the type 
and concentration of metal ions as well as the duration of their exposure. Overall, apoptosis was 
predominant after 24 h with both Co2+ (010 ppm) and Cr3+ (0500 ppm) ions, but high concentrations 
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induced mainly necrosis at 48 h. This same group also showed that Co2+ and Cr3+ induced mortality 
and apoptosis in J774 macrophages [96,97]. In a similar way, Akbar et al. [94] reported that exposure 
to high concentrations of metal ions (10 and 100 ȝM Cr6+, 100 ȝM Co2+) initiated apoptosis that 
resulted in decreased lymphocyte proliferation. A variety of soluble metals, including Co2+ and Cr3+, at 
a range of concentrations between 0.05 and 5 mM, were found to induce Jurkat T-lymphocyte DNA 
damage, apoptosis, and/or direct necrosis in a metal- and concentration-dependent manner [98]. 
From all these reports, it seems evident that CoCr nanoparticles and metal ions released from MoM 
implants have toxic effects in vitro and may pose a health risk to patients, regardless of whether their 
implant is well-functioning or failing. This toxicity helps explain the higher prevalence of adverse 
reactions to metal debris when compared to ceramic or polyethylene particles. The long-term effects of 
the exposure to these particles and ions remain a concern. Adverse health effects caused by accumulated 
metal particles in the periprosthetic tissues include osteolysis [99], inflammation, pain, and 
pseudotumours [100]. Case et al. [101] reported that the accumulation of metal particles in lymph 
nodes causes structural changes such as necrosis and fibrosis. Multiple reports [102109] have 
described patients with MoM implants who presented systemic adverse effects including neurological 
symptoms such as auditory impairment/deafness, visual impairment/blindness, peripheral 
neuropathy/dysesthesia of the extremities, poor concentration/cognitive decline, cardiomyopathy, and 
hypothyroidism. Several authors have associated these adverse effects with grossly elevated systemic 
Co blood levels. For example, Devlin et al. [110] reviewed 10 cases of suspected prosthetic hip-
associated cobalt toxicity and reported that these patients had findings consistent with cobalt toxicity, 
including thyroid, cardiac, and neurologic dysfunction. Similarly, Bradberry et al. [111] reviewed 
some cases in which patients exposed to high circulating concentrations of cobalt from failed hip 
replacements developed neurological damage, hypothyroidism, and/or cardiomyopathy. Finally, Clark 
et al. [112] reported that chronic exposure to MoM hip resurfacing is associated with subtle structural 
changes in the visual pathways and the basal ganglia in asymptomatic patients. Consistent with this 
notion, revision surgery to remove the defective metal hip prostheses resulted in lowered blood 
concentrations of metal ions and improved symptoms. Evidence is accumulating that systemic elevated 
concentrations of Co ions, due to the presence of wear debris, pose a serious health risk for some 
patients bearing CoCr MoM implants. There has also been speculation of a potential carcinogenic effect, 
however, recent reports [113,114] suggest that CoCr-containing hip implants are unlikely to be 
associated with an increased risk of cancer. 
3.2. Immunological 
Wear debris products generated at the articulation site may lead to a chronic inflammatory reaction 
in the periprosthetic region, resulting in implant failure caused by macrophage-stimulated osteolysis 
and aseptic loosening [115,116], which is the principal biological mechanism underlying prosthesis 
failure according to the National Joint Registry of England, Wales, and Northern Ireland [117]. 
It has been established and accepted that the presence of implant devices and wear debris incites a 
foreign body inflammatory reaction [118]. Metallic debris derived from alloy implants induces 
macrophage activation and triggers immune responses resulting in the release of an array of 
proinflammatory mediators including Tumor necrosis factor alpha (TNF)-Į, IL-1ȕ, IL-6, and  
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IL-8 [119]. TNF-Į, IL-1, and IL-6 induce osteoclast differentiation and maturation, which lead to bone 
resorption and, ultimately, aseptic loosening [120] (Figure 2). Dalal et al. [87] reported an increase in 
TNF-Į and IL-8 production by human osteoblasts, fibroblasts, and macrophages in response to 
different metal-based particles. Interestingly, they observed that the greatest cytokine responses of 
macrophages were to CoCr alloy particles. Posada et al. [88] also reported higher levels of secretion of 
IL-6, TNF-Į, and interferon (IFN)-Ȗ by resting monocyte-like cells (U937) after exposure to high 
concentrations of metal debris and the combination of metal debris and Co ions. Devitt et al. [121] 
investigated the in vitro effect of Co ions on a variety of cell lines by measuring production of IL-8 and 
Monocyte chemoattractant protein-1 (MCP-1) and found that Co ions enhanced the secretion of both 
cytokines in renal epithelial cells, gastric and colon epithelium, monocytes and neutrophils, and small 
airway epithelial cells. These investigations suggest a key role of Co ions in the immune response to 
wear debris. 
 
Figure 2. Schematic diagram of macrophage-stimulated osteolysis. 
Despite the understanding of implant-related cytokine/chemokine networks that are released by 
different peri-implant cell types, knowledge about the mechanisms mediating cellular interaction with 
debris particles and the subsequent activation of macrophages to produce and release the inflammatory 
mediators remain incomplete [122]. This has led to a number of studies seeking to define such 
mechanisms. Toll-like receptors (TLRs) are mainly found on monocytes and macrophages, and have 
been previously shown to activate the inflammatory cascade by triggering the expression of various 
cytokines (IL-1, IL-6, TNF-a), growth factors (macrophage colony stimulating factor-1), and 
chemokines (MIP-1 a, MCP-1), and activating various downstream signalling pathways (nuclear 
factor-țB (NF-țB), protein kinase B (AKT/PKB), and mitogen-activated protein kinase  
(MAPK) [123]. Tyson-Capper et al. [124] demonstrated that Co ions released from MoM joint 
replacement implants stimulate innate immune responses via direct activation of TLR4. Similarly, 
Potnis et al. [125] also demonstrated that Co-alloy particles trigger immune responses via the Toll-like 
receptor 4 (TLR4) myeloid differentiation primary response protein 88 (MyD88)-dependent signalling 
pathway. Since a key element in the initiation of the innate immune response against pathogens is the 
recognition of components commonly found on the pathogen, referred to as pathogen-associated 
molecular patterns (PAMP) [126], these studies suggest that wear particles could have a PAMP-like 
behaviour and bind to TLRs being expressed by macrophages, which then initiates signalling pathways 
leading to the stimulation of the immune response. Additionally, endogenous molecules generated upon 
tissue injury, termed damage-associated molecular patterns (DAMPs), directly activate TLRs [127]. 
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Proteins released by the damaged periprosthetic tissue include several heat shock proteins, biglycan, 
and fragments of extracellular molecules, such as oligosaccharides of hyaluronic acid and heparan 
sulphate, all of which are known activators of TLR2 and TLR4 [1]. 
Metal debris and ions can activate the immune system by inducing a delayed-type hypersensitivity 
reaction [38]. The most common sensitizing orthopaedic metals are nickel, cobalt, and  
chromium [38,128130]. It is thought that stimulated T-cells generate pro-osteoclastogenetic factors 
that can alter bone homeostasis [115] and therefore contribute to osteolysis. The prevalence of metal 
sensitivity among the general population is approximately 10% to 15% and the prevalence of metal 
sensitivity among patients with well-functioning and poorly functioning implants has been reported to 
be ~25% and 60%, respectively, as measured by dermal patch testing [38]. The response of  
metal-specific lymphocytes to metals as debris or in the form of metal ions has been linked to poor 
implant performance. Cell-mediated type-IV hypersensitivity reaction characterized by vasculitis with 
perivascular and intramural lymphocytic infiltration of the postcapillary venules, swelling of the 
vascular endothelium, recurrent localized bleeding, and necrosis has been reported following MoM hip 
replacements [131]. Lymphocyte infiltrates have also been reported in the soft-tissue masses, described 
as pseudo-tumours, following MoM resurfacing arthroplasty [21,132]. Additionally, metal-specific  
T-cells have been isolated from patients with contact dermatitis, indicating a T-cell-led inflammatory 
reaction against a metal-derived antigen [133]. For example, Cr exposure has been shown to upset the 
immunoregulatory balance between Th1 and Th2 cells that controls different immune effects or 
functions through the production of distinct cytokines [134]. In the work of these authors, the effects of 
cadmium, chromium, inorganic mercury, and inorganic lead exposure on the immune system were 
determined by measuring cytokine production of human peripheral blood mononuclear cells. Their 
results showed that the cytokines assayed were differentially affected by heavy metal exposure. Of 
particular interest, Cr significantly increased the production of IL-1ȕ while decreasing the production 
of IFN-Ȗ, IL-6, IL-8, and IL-10. 
It has been suggested that activation of T-cells following exposure to biomaterial particles is driven 
by macrophages and requires synergistic signals primed by both antigen presentation and 
costimulation [135137]. Bainbridge et al. [138] examined the expression of CD80 and CD86 
costimulatory molecules in U937 cells that had been exposed to titanium aluminium vanadium alloy 
(TiAlV) implant wear debris. This was compared to the expression of these costimulatory molecules in 
tissues taken from patients with aseptic loosening. They demonstrated the increased expression of 
costimulatory molecules in response to wear particles both at the bone implant interface and in vitro. 
These findings reinforce the hypothesis that macrophages have the potential to aid T-cell activation in 
response to metal or metal ions from orthopaedic implants, as well as to augment any T-cell  
mediated response. 
Several studies have described perivascular lymphocytes in tissue membranes around failed MoM 
implants apparently not associated with infection, and the authors have interpreted this inflammation 
as an immunologic reaction against metal ions or metal particles associated with those  
articulations [131,139142]. Polyzois et al. [143] reviewed the evidence of local and systemic toxicity 
of wear debris from total hip arthroplasty and found extensive evidence and experimental data 
supporting the fact that orthopaedic metals induce local immunological effects characterized by an 
unusual lymphocytic infiltration and cell-mediated hypersensitivity. Thomas et al. [144] reported the 
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case of a patient who developed eczema and impaired wound-healing following the fixation of an 
ankle fracture with titanium-based implants. Histological analysis of the tissue around the implant 
demonstrated inflammation primarily with lymphocytes, and a contact allergy to nickel and cobalt was 
found in the absence of titanium hyper-reactivity, raising the question of a prior unknown nickel 
exposure as the source of the complications. Similarly, Gao et al. [145] reported a case of systemic 
dermatitis caused by Cr (serum Cr level of 61.9 µg/L) after total knee arthroplasty. Another feature 
reported as a metal-induced systemic T-lymphocyte-mediated hypersensitivity reaction is the formation 
of periprosthetic soft-tissue masses in patients with MoM devices [132,146]. A delayed  
T-lymphocyte-mediated self-perpetuating response can also create extensive tissue damage [122]. To 
date, the only means to predict/diagnose those individuals that will have an excessive immune 
response to metal exposure that may lead to premature implant failure are lymphocyte transformation 
test and patch testing (for skin reactions). However, they are not so useful in the evaluation of deep 
tissue metal allergy [122,145]. Although complications in metal-allergic patients appear to be 
generally rare [115], metal nanoparticles and high metal ion concentrations remain a concern as they 
could trigger early events leading to implant failure or a shorter implant lifespan in sensitized patients. 
Moreover, it remains unclear whether sensitization is a direct cause of implant loosening and failure, or 
if it is a consequence of particle loading due to device loosening. 
3.3. Gene Expression 
Over the past few years numerous investigations have been carried out to study the effects of 
different ions and particulate wear debris on the expression of an array of cytokine and toxicology 
related genes in vitro. TNF-Į, IL-1, and IL-6 are cytokines that have been reported to play a central 
role in the induction of implant osteolysis [147,148]. Extensive work has been carried out on cytokine 
production by macrophages in response to wear debris. Sethi et al. [40] studied the macrophage 
response to cross-linked ultra-high molecular weight polyethylene (UHMWPE) and compared it to 
conventional UHMWPE as well as TiAlV and cobalt-chrome alloy (CoCr). At 24 and 48 h, macrophages 
cultured on TiAlV and CoCr alloy expressed higher levels of IL-1Į, IL-1ȕ, IL-6, and TNF-Į than when 
grown on UHMWPE materials according to real time reverse transcription polymerase chain reaction 
(qRT-PCR) analysis. Jakobsen et al. [149] compared surfaces of as-cast and wrought CoCrMo alloy and 
TiAlV alloy when incubated with mouse macrophage J774A.1 cells and reported a significant increase in 
the levels of expression of TNF-Į, IL-6, IL-1Į, and ȕ from cells incubated with alloys compared to  
non-stimulated cells. Garrigues et al. [150] used microarrays to investigate alterations in the phenotype 
of macrophages as they interact with UHMWPE and TiAlV alloy particulate wear debris. Their 
findings further validate the important roles of TNF-Į, IL-1ȕ, IL-1Į, IL-6, MIP1Į, and MIP1ȕ in 
osteolysis. In a recent study, Posada et al. [43] examined the ability of the metal debris and Co ions to 
induce general toxicology-related gene expression of human monocyte-like U937 cells. In some 
experiments, they pre-treated the cells with Co ions prior to exposure to CoCr particles, in order to 
simulate the in vivo situation where a patient may receive a second MoM implant in either a bilateral 
or a revision procedure. Analysis of qRT-PCR results found significant up-regulation of inducible 
nitric oxide synthase (NOS2) and Bcl2-associated athanogene (BAG1) in Co pre-treated cells which 
were subsequently exposed to Co ions and debris. They showed that metal debris was more effective 
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as an inducer of gene expression when cells had been pre-treated with Co ions. Overexpression of 
NOS2, which leads to an over production of NO, could have a predominant role in the inflammation 
and acidification of the peri-implant microenvironment, which in turn could exacerbate the corrosion 
of the nanoparticles. Co-expression of BAG1 and Bcl-2 has been shown to increase protection from 
cell death [151,152]. Consequently, up-regulation of BAG1 could be interpreted as part of a defence 
mechanism for delaying cell death in response to metal toxicity, particularly Co toxicity, in this case. 
Since the main gene expression fold changes were observed in cells pre-treated with Co ions, patients 
with a MoM implant undergoing revision surgery or receiving a second MoM device may potentially 
be at higher risk of implant failure. 
As well as macrophages, other cell types have been reported as being involved in the biological 
response to implant wear debris. As a result, there are similar studies on monocytes, lymphocytes, 
osteocytes, and osteoblasts. For example, the effects of CoCr particles on osteocytes were tested by 
Kanaji et al. [148]. CoCr treatment of murine long bone osteocyte Y4 (MLO-Y4) osteocytes 
significantly up-regulated TNFĮ gene expression after 3 and 6 h and TNF-Į protein production after 24 h, 
but down-regulated IL-6 gene expression after 6 h. MG-63 osteoblasts were treated by Vermes et al. [153] 
with titanium, titanium alloy, chromium orthophosphate, polyethylene, and polystyrene particles and 
they reported that each type of particle significantly suppressed procollagen alpha1[I] gene expression 
(p < 0.05), whereas other osteoblast-specific genes (osteonectin, osteocalcin, and alkaline phosphatase) 
did not show significant changes. The effect of particulate derivatives of nickel and cobalt alloys on 
the mRNA levels of chemokine receptors CCR1 and CCR2 on monocytes/macrophages from whole 
blood were analysed by Fujiyoshi and Hunt [154]. Although there were no significant differences in 
the level of CCR1 mRNA in monocytes/macrophages incubated with NiCr particulates, there was a 
down-regulation in the level of CCR2 in cells incubated with NiCr and CoCr particles. All these 
investigations indicate that wear debris and metal ions derived from MoM implants can cause an 
adverse tissue response by modulating gene expression on several types of cells, which suggests that 
osteolysis and subsequent aseptic loosening is the result of the concerted action of the different  
cell types. 
Previous studies have stated that ions released from the wear debris could also affect gene expression. 
It has been reported that Cr+3 and Co+2 ions could induce damage to proteins in macrophage-like cells 
in vitro, probably through the formation of reactive oxygen species (ROS) [155,156]. U937 cells were 
exposed to Cr+6 and Co+2 ions by Tkaczyk et al. [157]. Cr+6 induced the protein expression of  
Mn-superoxide dismutase, Cu/Zn superoxide dismutase, catalase, glutathione peroxidase, and heme 
oxygenase-1 (HO-1) but had no effect on the expression of their mRNA, whereas Co+2 induced the 
expression of both protein and mRNA of HO-1 only. Co+2 had no effect on the expression of the other 
proteins. The overexpression of HO-1 has been suggested to play an important role in cellular protection 
against oxidant-mediated cell damage [158]. This suggests that the results from Tkaczyk et al. [157] 
show that Cr and Co ions cause oxidant-mediated cell damage. Type-I collagen gene expression was 
evaluated by Hallab et al. [159] after treating MG-63 cells with increasing concentrations (from 0.001 
to 10 mM) of a variety of metal ions including Co and Cr. At toxic concentrations (1 mM), Co 
depressed osteoblast function by significantly decreasing the levels of type I collagen gene expression 
to 40% of control values. Queally et al. [160] showed that 10 ppm Co ions induce chemokine secretion 
in primary human osteoblasts by measuring the up-regulation of IL-8 and MCP-1 gene expression in 
Lubricants 2015, 3 553 
 
 
osteoblasts stimulated with 010 ppm Co2+. The level of expression of one of the principal proteinases 
capable of degrading native fibrillar collagens in the extracellular matrix, MMP-1, and its tissue 
inhibitors (TIMP-1) in U937 cells exposed to Co2+ and Cr3+ ions for 24 h, was determined by  
Luo et al. [161] who showed that these ions induce up-regulation in a dose-dependent manner. Their 
expression was studied to gain insight into the regulation of extracellular matrix degradation and tissue 
remodelling around hip prostheses. Altered expression of MMP-1 and TIMP-1 in the periprosthetic 
tissues has led to the hypothesis that their imbalance could contribute to the loosening of total hip 
prosthesis [162]. The findings from Luo et al. [161] suggest that Co and Cr ions can up-regulate the 
MMP-1 expression in vivo. These studies provide more evidence of potential gene expression 
modulation by wear debris and ions derived from MoM implants. 
Receptor activator of nuclear factor-țB ligand (RANKL), its receptor, receptor activator of nuclear 
factor-țB (RANK), and its soluble inhibitor osteoprotegerin (OPG) are recognized as key regulators of 
osteoclast formation that regulate bone resorption in both health and disease [163]. Several studies 
have demonstrated the expression of mRNA encoding RANKL, OPG, and RANK in peri-implant 
tissues associated with osteolytic zones [164167]. Jiang et al. [168] demonstrated a significantly elevated 
gene expression of RANKL in CoCr particle-challenged osteoblasts. Similarly, Pioletti and Kottelat [169] 
showed an increase of osteoblast gene expression for RANKL after exposure to Ti particles.  
Zijlstra et al. [170] determined the effects of Co and Cr ions on the expression of bone turnover 
regulatory proteins RANKL and OPG on human osteoblast-like cells. They found that the RANKL/OPG 
ratio increased after 72 h of exposure to 10 ȝg/L Co, 1 ȝg/L Cr, and higher, and at 1 ȝg/L Co + Cr and 
higher, indicating net bone loss. These findings are interesting since they seem to suggest that even in 
well-functioning MoM implants with systemic Co and Cr levels around 1 ȝg/L, local periprosthetic 
osteolytic reactions may take place. In a pilot study in our laboratory, gene expression of RANK, 
RANKL, and OPG in peripheral blood from six patients that had MoM hip implants for at least one 
year was investigated and correlated with the whole blood metal ion levels at the time of the analysis. 
There was a significant up-regulation of RANK and RANKL and significant down-regulation of OPG 
when compared to controls (no implant) (Figure 3). It has been suggested that the RANKL/OPG ratio 
is raised significantly in patients with severe osteolysis and that this imbalance is involved in bone 
resorption mechanisms [171]. Since OPG was down-regulated, patients had higher ratios (27.69 ± 10.53, 
mean ± SEM) when compared to controls (1 ± 0.15, mean ± SEM), suggesting an imbalance in the 
bone turnover system favouring bone resorption. However, a clear relationship between RANKL/OPG 
ratios and ion levels could not be established. Although changes in gene expression were identified, the 
lack of pre-surgery data made it impossible to determine whether the presence of the MoM implant 
was the cause of such changes. 
All the studies mentioned in this section have been carried out in order to understand how wear 
debris affects the levels of expression of genes involved in osteolysis in tissues surrounding the joint 
implant. They suggest different mechanisms for transcriptional activation of the genes investigated, 
which could indicate that gene expression is modulated in a dose- and particle-dependent manner and 
as the result of several signals coming together. 
Thus, the biological responses to metal wear debris are complex, involving regulation at different 
cellular and molecular levels to try and maintain intra- and extra-cellular homeostasis. When cells fail, 
they tip the balance towards inflammation and acidification. This acidification of the peri-implant 
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microenvironment in turn enhances the corrosion of the nanoparticles and release of metal ions, which 
exacerbates the adverse reaction ultimately resulting in osteolysis and subsequent aseptic loosening. 
 
Figure 3. Fold variations of target genes in blood samples from controls and from patients 
with MoM hip implants. Results are mean values ± standard deviation (SD) (six biological 
samples with three technical replicates per gene assayed) expressed as the negative 
reciprocal. * Significantly different from control values by Analysis of variance (ANOVA) 
followed by Dunnets comparison test (p < 0.05) (Posada et al., unpublished data). 
4. Discussion 
Since the recall of MoM devices in 2010, the trends in bearing surface materials have changed, 
showing ceramic-on-polyethylene becoming more popular (Figure 4). The use of MoM has declined 
dramatically and the proportion of MoM resurfacing implants has decreased from a peak in 2006 to 
account for only 1.1% of implants in 2013 [117]. Although the recalls have taken most of the defective 
implant designs off the market, there are still tens of thousands of patients in the UK alone with these 
implants still in situ. 
 
Figure 4. Number of primary hip replacements registered in 2013 by bearing surface. 
Metal-on-polyethylene (MoP): 45,944. Metal-on-metal (MoM, includes both total and 
resurfacing): 1014. Ceramic-on-polyethylene (CoP): 14,258. Ceramic-on-ceramic (CoC): 
14,433. Ceramic-on-metal (CoM): 32. Others/unsure: 593 [3]. 
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The Medicines and Healthcare Products Regulatory Agency (MHRA) issued information and 
advice about the follow-up of both symptomatic and asymptomatic patients implanted with MoM hip 
replacements, which include appropriate imaging (Metal Artifact Reduction Sequence (MARS) 
MRI/ultrasound), whole blood metal ion levels, and situations where revision may need to be 
considered. The MHRA has suggested that MARS MRI scans (or ultrasound scans) should carry more 
weight in decision-making than blood ion levels alone, and combined whole blood cobalt and 
chromium levels of greater than 7 ppb (7 ȝg/L), indicates potential for soft tissue reaction [172]. This 
decision is becoming more established among orthopaedic surgeons, but it does leave the quandary of 
the patients with circulating metal ion levels in several hundreds of µg/L and normal cross-sectional 
imaging. For these patients, many of whom have a well-functioning implant, it is difficult to 
understand whether or not the effects of particles and ions will ultimately impact their health locally or 
distally to their implant. It remains unclear whether these patients should be advised on a revision to 
avoid long-term systemic adverse effects on organs such as the heart and brain. It is worth noting that 
the 7 ppb threshold is a means of understanding how well the hip is performing in vivo [173], and 
revision is only considered if imaging is abnormal and/or blood metal ion levels rise [174]. 
Additionally, although this threshold is not based on soft tissue damage, levels of greater than 7 ppb 
are associated with significant soft-tissue reactions and failed MoM hips [63]. 
Although there has been widespread research on the various functions of different cytokines, 
questions concerning how inflammatory responses are triggered by wear particles remain largely 
unanswered. Specific organelles could play an important role in the cellular response triggered by wear 
particles. A growing body of evidence has suggested a role for endoplasmic reticulum (ER) stress in 
initiating inflammation, which is now thought to be fundamental to the pathogenesis of inflammatory 
diseases [175,176]. There is evidence suggesting that metal particles can cause increasing ER stress in 
various types of cells [177,178]. This presents the possibility that wear particles, produced  
around the prosthesis, have the potential to stimulate ER stress and thus may play a role in  
particle-induced osteolysis. 
Chronic environmental exposure to some metal compounds, including arsenic, nickel, chromium, 
and cadmium, has been known to induce cancers and other diseases in exposed individuals [179]. 
While it has been shown that these metals disturb a vast array of cellular processes, such as redox state 
and various intracellular stress-signalling pathways, their ability to induce acute and/or chronic 
pathologies remains poorly understood. Sources of potential environmental exposure to these metals 
include occupational exposure and environmental contamination from industrial production [180]. 
Additionally, with all the evidence on particles and ions derived from metal orthopaedic implants, such 
replacements should be considered as an additional source of exposure. Emerging epidemiological 
studies show that the carcinogenic potential of some toxic metals may involve epigenetic changes, 
including silencing of DNA repair and tumor-suppressor genes [179]. The combinations of 
mechanisms, which confer long-term programming to genes and could bring about a change in gene 
function without changing gene sequence, are termed epigenetic [181]. As artificial articulations are 
being implanted in younger people, epigenetic studies could help assess how long-term exposure to 
metal debris and ions could bring about epigenetic changes altering gene expression which may have 
significant health-related consequences for these patients. 
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5. Conclusions 
Despite the clinical success of hip replacements, this review has summarised some of the work 
addressing the still-present concern regarding the toxicity of metal particles and ions produced at the 
articulation site of a MoM implant. A vast literature on the effects of different kinds of debris as well 
as ions exists with many groups engaged in the discussion of mechanisms involved. 
The potential dangers to patient health from CoCr alloy wear debris generation and the release of 
Co and Cr ions into circulation have been recognized. However, until the regulations for thoroughly 
testing the safety of medical devices such as hip replacements and other orthopaedic implants is more 
stringent, there is a very real possibility that 20 years from now we will be reading articles on the 
award of compensation for the next generation of articulations. 
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